Cytokine storms: CAR T-cell hyperinflammatory response distinct from cytokine release syndrome?
Description: Cytokine release syndrome (CRS) is a relatively well-described toxicity of CAR T-cell therapy. However, their may be delayed manifestations of CRS, such as disseminated intravascular coagulation (DIC) and macrophage activation syndrome (MAS). In this interview, Nirali Shah, MD, of the National Cancer Institute, National Institutes of Health, Bethesda, MD, discusses what her group observed in patients with acute lymphoblastic leukemia (ALL) following anti-CD22 CAR T-cell infusion. Dr Shah highlights the fact that we are only just starting to understand the interplay between these factors. In addition, she discusses the need to identify additional therapies to treat these side effects. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Shared By : VJHemOnc
Posted on : 01/05/18
Added : 6 months ago